Gilead Sciences, Inc has begun enrolling patients in a phase-II clinical trial of its investigational integrase-based, single-tablet, once-daily regimen of elvitegravir, GS 9350 and Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) for the treatment of HIV-1 infection.
The details can be read here.
No comments:
Post a Comment